Life Sciences
/
AI DEPLOYED
WHERE YOUR TRIALS ENROLL.
Triomics is already working with 4 of the top 10 U.S. cancer centers and 10+ NCI-designated cancer centers. The same sites that run your oncology trials. That deployment footprint becomes your competitive advantage: faster recruitment, real-time feasibility, and protocol intelligence informed by the actual patient populations.
Top 10 U.S. cancer centers
4
88
4
/10
NCI center partners
10
88
10
+
Lift in treatment trial accruals
30
88
30
%
Faster Pre-Screening
70
88
70
%
Why this matters
/
This is not a site performance problem. It is a data problem.
Oncology eligibility depends on information scattered across years of notes, scans, labs, pathology, genomics, and outside records. No team can manually read every chart at scale, so feasibility still relies on surveys, forecasts rely on partial EHR signals, and eligibility review varies because the source data is hard to assemble consistently.
What’s different
/
One AI platform, deployed at the sites, sponsor- ready outputs.
We are already running inside leading cancer centers and sites, screening every patient against every active trial. That same platform provides visibility into screening throughput, fully-eligible patient counts, and protocol-level performance.
Capabilities
/
Built for sponsor oncology clinical development.
Four sponsor-facing capabilities, all powered by deployments already running at investigator sites.
Accelerated enrollment.
PRISM screens upcoming patients against open protocols at the site, and refreshes matches before each visit. Coordinators walk in with cited, prioritized candidates already on their worklist. Sponsors benefit from faster FPI and LPI timelines, lower screening burden on sites, and a recruitment motion that is proactive.
.webp)
.webp)
Screening throughput visibility.
Sponsors see, at protocol level, how many patients have been pre-screened, how many were ruled out, how many were flagged for follow-up, and how the screening funnel compares.
Precise feasibility.
Run a protocol’s eligibility criteria against the active patient populations at participating sites and get fully-eligible patient counts in hours, not weeks. Real-time, EHR-grounded feasibility, to inform site selection and enrollment targets.
.webp)
.webp)
Better insights for trial design.
We surface the eligibility criteria that are disqualifying patients, and how often each criterion is the only thing standing between a patient and enrollment. Sponsors use that signal to refine inclusion and exclusion, in subsequent amendments, and in future protocol designs.
Partners
/
Working with leading oncology sponsors.
We’re partnered with sponsors across early- and late-phase oncology development. Indications span solid tumors and hematologic malignancies.
Built for the enterprise
/
Site-deployed. Sponsor-ready.
Triomics deployments are governed by site agreements. Sponsor access to any outputs or de-identified insights runs through site-approved data-sharing models and is fully aligned with HIPAA, IRB, and CTA requirements. No PHI flows to sponsors. Only the cohort and protocol signals.
HIPAA
SOC 2
IRB-aligned
CTA-compatible
Site-governed
Get started
Triomics
SEE THE PLATFORM
LIVE IN ACTION
A 30-minute working session with our team. Use our synthetic-data sandbox, or sign a BAA to upload your own data.